Prognostic value of myeloid differentiation primary response protein 88 in type II diabetes mellitus in non-obese NAFLD: A case-control study from Assam
SJ Das, S Dutta, D Tiwari, TK Basumatary, N Kashyap… - Human Gene, 2024 - Elsevier
Background and aim Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals is a
global epidemic. NAFLD is related with type II diabetes mellitus (T2DM); thus may have a …
global epidemic. NAFLD is related with type II diabetes mellitus (T2DM); thus may have a …
The gut-liver nexus: exploring gut microbiota dysbiosis in non-alcoholic fatty liver disease and its therapeutic implications
DM Swamikkannu, S Dasarapu, RPV Siva… - Egyptian Liver …, 2024 - Springer
The human gut microbiota (GM) is a diverse ecosystem crucial for health, impacting
physiological processes across the host's body. This review highlights the GM's involvement …
physiological processes across the host's body. This review highlights the GM's involvement …
Novel Noninvasive Paraclinical Study Method for Investigation of Liver Diseases
N Gyorfi, AR Gal, A Fincsur, K Kalmar-Nagy, K Mintal… - Biomedicines, 2023 - mdpi.com
Based on a prior university patent, the authors developed a novel type of bioimpedance-
based test method to noninvasively detect nonalcoholic fatty liver disease (NAFLD). The …
based test method to noninvasively detect nonalcoholic fatty liver disease (NAFLD). The …
Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
A Al-Shargi, AA El Kholy, A Adel, M Hassany… - Biomedicines, 2023 - mdpi.com
Metabolic dysfunction-associated steatotic liver disease (MASLD) includes patients with
hepatic steatosis and at least one of five cardiometabolic risk factors. Xanthine oxidase (XO) …
hepatic steatosis and at least one of five cardiometabolic risk factors. Xanthine oxidase (XO) …
Comparison of fatty liver index with fibroscan in non-alcoholic fatty liver disease
Aim: To evaluate the sociodemographic and clinical attributes of study participants
concerning their ultrasound grading with FibroScan and FLI values. Settings and Design: A …
concerning their ultrasound grading with FibroScan and FLI values. Settings and Design: A …
Recognition of Diffuse Hepatic Steatosis
D Yevdokimov, V Gorikhovskii - 2023 33rd Conference of Open …, 2023 - ieeexplore.ieee.org
Since the COVID-19 pandemic, chest computed tomography has become a common
practice, with the liver and spleen being studied in addition to the lungs and heart …
practice, with the liver and spleen being studied in addition to the lungs and heart …
CORRELATION BETWEEN HEPATIC STEATOSIS AND LIVER FIBROSIS WITH CAROTID INTIMA-MEDIA THICKNESS AND CAROTID PLAQUES IN PATIENTS WITH …
TTK Tuong, HM Duc, TND Hong - Tạp chí Y học Việt Nam, 2023 - tapchiyhocvietnam.vn
Background: Nonalcoholic fatty liver disease (NAFLD) is currently the leading cause of
chronic liver disease. Approximately 10 to 30% of patients with NAFLD progress to …
chronic liver disease. Approximately 10 to 30% of patients with NAFLD progress to …
[PDF][PDF] UNIVERSITY OF MEDICINE AND PHARMACY „CAROL DAVILA” BUCHAREST FACULTY OF MEDICINE DOCTORAL SCHOOL GASTROENTEROLOGY
NONAF LIVER - umfcd.ro
In recent decades it has become increasingly evident that non-alcoholic fatty liver disease
(NAFLD) and non-alcoholic steatohepatitis (NASH) are leading causes of liver disease in …
(NAFLD) and non-alcoholic steatohepatitis (NASH) are leading causes of liver disease in …
[HTML][HTML] Learning Objective Performance Indicators
DH Spach, MA Corcorran, HCVI Data - hiv.uw.edu
Background Pneumocystis pneumonia (PCP) is a leading cause of morbidity and mortality in
people with HIV. The causative organism, Pneumocystis jirovecii, is classified as a fungus …
people with HIV. The causative organism, Pneumocystis jirovecii, is classified as a fungus …